First Patient Dosed in Akeso’s Phase III Trial of Cadonilimab for Resectable Gastric Cancer
Hong Kong, August 20, 2025 — Akeso, Inc. (9926.HK) has announced the enrollment and dosing of the first patient...
Advertisement
FDA Approves Merck Animal Health’s BRAVECTO QUANTUM – First Once-Yearly Injection Flea & Tick Protection for Dogs
July 10, 2025 – The U.S. Food and Drug Administration (FDA) has approved BRAVECTO® QUANTUM (fluralaner for extended-release injectable...
FDA Launches PreCheck Program to Strengthen U.S. Drug Manufacturing
August 7, 2025 – The U.S. Food and Drug Administration (FDA) has announced the launch of FDA PreCheck, a...
IQVIA and Veeva Forge Landmark Global Partnership, Ending Legal Disputes
Research Triangle Park, NC & Pleasanton, CA – August 20, 2025 – After years of high-profile legal battles, life...
Affordable Alternative: Glenmark Announces U.S. Launch of Micafungin for Injection USP
Mahwah, New Jersey, August 19, 2025 – Glenmark Pharmaceuticals Inc., USA is set to introduce Micafungin for Injection USP...
FDA Approves Precigen’s PAPZIMEOS, First Immunotherapy for Recurrent Respiratory Papillomatosis
August 19, 2025 — Germantown, MD – Precigen, Inc. (NASDAQ: PGEN) today announced that the U.S. Food and Drug...
Nike’s Phil and Penny Knight, $2B gift to Oregon Health & Science University’s Knight Cancer Institute
Portland, Oregon – August 14, 2025 – In what marks the largest single donation ever made to a U.S....
Eli Lilly $1.3B Collaboration with Boston based Superluminal to develop Small Molecule Therapy for Cardiometabolic and Obesity.
Boston, MA – August 14, 2025 – Superluminal Medicines, a pioneering drug discovery company integrating artificial intelligence, machine learning,...
Strand Therapeutics Secures $153M for mRNA Technology
By NewsDesk — Aug. 7, 2025 (America/New York) Strand Therapeutics, a Boston‑based startup pioneering programmable messenger RNA (mRNA) therapies, closed a $153 million Series B...
FDA Grants Accelerated Approval for EMRELIS™ (telisotuzumab) in Advanced NSCLC With High c-Met Overexpression
NORTH CHICAGO, Ill., May 14, 2025 — AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration...
Advertisement
